Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.
Recently, there has been increasing interest in the use of targeted molecular agents for the treatment of malignant gliomas. These agents are generally well tolerated but have demonstrated only modest activity. In this article, the current status of targeted molecular agents for malignant gliomas will be reviewed and strategies to improve their effectiveness will be discussed.
Wen
Patrick Y
PY
Harvard Medical School, Dana-Farber/Brigham and Women's Cancer Center, SW430D, Boston, MA 02115, USA. pwen@partners.org
Kesari
Santosh
S
Drappatz
Jan
J
D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D006131:Growth Inhibitors; D006133:Growth Substances; D006801:Humans
D004791:Enzyme Inhibitors; D006131:Growth Inhibitors; D006133:Growth Substances